Clinical Trial Update: APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors [Phase 1]

View source ↗

Summary

Ascentage Pharma is conducting a Phase 1 trial of APG-115 alone or in combination with APG-2575 in children with recurrent or refractory neuroblastoma or other …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma
• Solid Tumor

Drugs mentioned

• APG-115 (APG-115)
• APG-2575

Snippet

Sponsor: Ascentage Pharma Group Inc. | Conditions: Neuroblastoma, Solid Tumor | Phase 1 | Status: RECRUITING